NDC 0409-0805-11 - Cefazolin
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 0409-0805
- Requested NDC
- 0409-0805-11
- Package NDCs from labels
- 0409-0805-11, 0409-0805-01
- Manufacturer
- General Injectables & Vaccines, Inc
- Effective date
- 2019-01-18
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Cefazolin - General Injectables & Vaccines, Inc | General Injectables & Vaccines, Inc | 2019-01-18 | HUMAN PRESCRIPTION DRUG LABEL |
| Cefazolin - Hospira, Inc. | Pfizer Healthcare India Private Limited | Hospira, Inc. | Pfizer Healthcare India Private Limited | 2018-06-05 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 0409-0805-01 | EA - Each | 0409-0805 | 48f17daf-c68c-4522-94f6-daf178256e29 | 1 | 2012-07-24 |
| 0409-0805-11 | EA - Each | 0409-0805 | c6b0f7e9-5b89-46ad-9717-ae0d15f2c7c9 | 1 | 2016-04-04 |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | DailyMed label | SPL version | Uploaded |
|---|---|---|---|---|---|
| Cefazolin Sodium | ACTIVE INGREDIENT | P380M0454Z | CEFAZOLIN INJECTION, POWDER, FOR SOLUTION [HOSPIRA, INC.] | 3 | |
| Cefazolin | ACTIVE MOIETY | IHS69L0Y4T | CEFAZOLIN INJECTION, POWDER, FOR SOLUTION [HOSPIRA, INC.] | 3 | |
| Cefazolin Sodium | ACTIVE INGREDIENT | P380M0454Z | CEFAZOLIN (CEFAZOLIN SODIUM) INJECTION, POWDER, FOR SOLUTION [GENERAL INJECTABLES & VACCINES, INC] | 2 | |
| Cefazolin | ACTIVE MOIETY | IHS69L0Y4T | CEFAZOLIN (CEFAZOLIN SODIUM) INJECTION, POWDER, FOR SOLUTION [GENERAL INJECTABLES & VACCINES, INC] | 2 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Cefazolin | CEFAZOLIN | Hikma Pharmaceuticals USA Inc. | 26de1ce9-06a9-486f-b27d-2ac635f018d1 | 2026-05-14 | Warnings, Adverse reactions | P380M0454Z |
| Cefazolin | CEFAZOLIN | Civica, Inc. | 9ea55207-6d86-401e-b9b9-73c9534a233f | 2026-05-14 | Warnings, Adverse reactions | P380M0454Z |
| Cefazolin | CEFAZOLIN | Hikma Pharmaceuticals USA Inc. | 1dc9de56-e259-4546-a1db-23119a8a088e | 2026-05-14 | Warnings, Adverse reactions | P380M0454Z |
| Cefazolin | CEFAZOLIN | WG Critical Care, LLC | 4f3a9248-a354-4c77-bf5b-9eed38f00219 | 2026-02-27 | Warnings, Adverse reactions | P380M0454Z |
| Cefazolin | CEFAZOLIN | WG Critical Care, LLC | 00dd6da7-50a8-44c9-b2dc-7948973df392 | 2026-01-07 | Warnings, Adverse reactions | P380M0454Z |
| Cefazolin | CEFAZOLIN | Civica, Inc. | c24e604f-16ca-4945-8e9d-277cc67a8c68 | 2025-11-20 | Warnings, Adverse reactions | P380M0454Z |
| Cefazolin | CEFAZOLIN | Civica, Inc. | 1367568c-7d27-479f-a4c5-58e99942f686 | 2025-11-01 | Warnings, Adverse reactions | P380M0454Z |
| CEFAZOLIN | CEFAZOLIN | Henry Schein, Inc. | 197d5702-2c20-480e-8246-4d0d21f871be | 2025-10-27 | Warnings | P380M0454Z |
| CEFAZOLIN | CEFAZOLIN | Henry Schein, Inc. | 5a8c4bb2-a75e-4d7d-91fb-9a95f04fc94b | 2025-10-27 | Warnings, Adverse reactions | P380M0454Z |
| Cefazolin | CEFAZOLIN | ProPharma Distribution | 3d5cc73c-8a41-b285-e063-6294a90a609f | 2025-08-27 | Warnings, Adverse reactions | P380M0454Z |
| Cefazolin | CEFAZOLIN | Hikma Pharmaceuticals USA Inc. | 570d2583-9ce7-4941-bf7c-6ebc783c0f2b | 2025-07-25 | Warnings, Adverse reactions | P380M0454Z |
| Cefazolin | CEFAZOLIN | Apotex Corp. | 0422fe47-c372-494f-bac2-612f550b44a4 | 2025-07-15 | Warnings, Adverse reactions | P380M0454Z |
| Cefazolin | CEFAZOLIN | WG Critical Care, LLC | f17160d4-fc42-4f9c-abb8-d04f01ae6dd1 | 2025-04-07 | Warnings, Adverse reactions | P380M0454Z |
| Cefazolin Sodium | CEFAZOLIN SODIUM | B. Braun Medical Inc. | 17f8f038-c204-4dab-80d7-6f7ac41ddbec | 2025-03-10 | Warnings, Adverse reactions | P380M0454Z |
| Cefazolin | CEFAZOLIN | Sandoz Inc | 18e7366a-1b3e-4010-8f4a-dd559d4f2146 | 2025-02-05 | Warnings, Adverse reactions | P380M0454Z |
| CEFAZOLIN | CEFAZOLIN SODIUM | Samson Medical Technologies, L.L.C. | cf13db9c-d8a1-489f-9aa0-fc70839d4bbc | 2025-01-08 | Warnings, Adverse reactions | P380M0454Z |
| Cefazolin | CEFAZOLIN | Hikma Pharmaceuticals USA Inc. | 6c7761d3-c154-4802-9876-627cd42913f0 | 2024-12-31 | Warnings, Adverse reactions | P380M0454Z |
| Cefazolin Sodium | CEFAZOLIN SODIUM | Direct_rx | 22dfc2e4-07a7-8d13-e063-6394a90a3e9f | 2024-09-24 | Warnings, Adverse reactions | P380M0454Z |
| Cefazolin | CEFAZOLIN | Hikma Pharmaceuticals USA Inc. | 06091653-e568-4e82-acc7-aefbce16de17 | 2024-04-18 | Warnings, Adverse reactions | P380M0454Z |
| Cefazolin | CEFAZOLIN | Qilu Pharmaceutical Co., Ltd. | e8bd9e95-8af5-416b-b58c-e1dbe3d052ac | 2023-12-18 | Warnings, Adverse reactions | P380M0454Z |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.